Clinical Trials
14 trialsNCT06475235 2026-02-20
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT03010176 2025-10-29
MK-1454-001
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT03249792 2025-07-24
MK-2118-001
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT03884556 2025-07-02
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Trishula Therapeutics, Inc.
Phase 1 Completed
NCT05878691 2024-07-22
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas.
Glenmark Specialty S.A.
Phase 1 Active not recruiting
NCT03934814 2024-07-01
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
I-Mab Biopharma US Limited
Phase 1 Completed
NCT04920383 2024-03-01
NEON-2
Alpine Immune Sciences, Inc.
Phase 1 Terminated
NCT04609579 2024-01-30
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Stingthera, Inc.
Phase 1 Terminated
NCT03229278 2023-12-06
Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Rutgers, The State University of New Jersey
Phase 1 Completed
NCT05296772 2023-09-06
Phase 1 First-in-human Study of JS014
Anwita Biosciences
Phase 1 Unknown
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT03815682 2022-12-06
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Repertoire Immune Medicines
Phase 1 Terminated
NCT01986426 2018-10-03
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
Phase 1 Completed